Dr Akhil Santhosh reviewed all the newer drugs in solid oncology and taught the budding oncologist. eGurukul series taking a new shape with full blown exam viva with Dr Amol Akhade. #eGurukul #YoungOncologist #YMO

Watch & Wait in rectal cancer: Journal of Clinical Oncology study: Distant mets in local regrowth pts = 22.8% vs. 10.2% in TME pts (P≤.001) LR → higher risk of mets even if salvageable. DM-free survival: 75% vs. 87% Should we rethink our Watch & Wait strategy? #OncoTwitter @ESMO ASCO LARVOL

#ESMOBreast25 Recent Advances In Treatment For Hr+ Her2- Breast Cancer from Dr. Sara Tolaney wonderful presentation👇 #ESMOAmbassadors ESMO - Eur. Oncology

The fascinating story of Thalidomide: how this most notorious drug on the planet, banned in the 1960s, made an incredible comeback and revolutionized the treatment of myeloma. I will also highlight one person whose role is not recognized: Without Dr. Leif Bergsagel there will

#ASCO25 Oral paclitaxel (DHP107) vs IV paclitaxel in HER2– mBC PFS ➡️ 10.0 vs 8.5 mo OS ➡️ 32.9 vs 32.5 mo ORR ➡️ 45.8% vs 39.7% PNP ➡️ 37.9% vs 48.3% Gr≥3/4 neutropenia ➡️ 67.2% vs 29.7%! 💥Oral paclitaxel shows non-inferior efficacy with better convenience

Infact we have 6 regimens now in advanced HCC . Nivo plus IPI data ( checkmate 9DW ) updated for comparison OncoAlert

OncoAlert Dra. María Natalia Gandur Quiroga Alizée Camps - - Maléa Biagio Ricciuti, MD, PhD Emre Yekedüz Hidehito HORINOUCHI Fadi Haddad, MD This is by far the most important list! Thank you, OncoAlert and Dr Joseph McCollom DO for putting this together!! It’s not just about starting the best treatment but also about keeping our patients on it for the long term and effectively managing any adverse events. That’s the key! A

Phase 2 Trials on Induction Chemoimmunotherapy, Radiation, and Consolidation IO in Stage III EGFR–Wild-Type NSCLC Source: dailynews.ascopubs.org/do/evaluating-… #lcsm #ASCO25

🚨DESTINY GASTRIC-04🚨 M1 Her2+ Gastric Cancer, 2nd line therapy 🔎Trastuzumab Deruxtecan vs Ramucirumab + Paclitaxel ✅⬆️OS with T-DXd supporting use as SOC! Simultaneous pub in NEJM here: nejm.org/doi/full/10.10… #ASCO25

ASCENT-04: SG+ pembro vs chemo+ pembro for PD-L1+ mTNBC in 1st line setting ⬆️mPFS 11.2m vs 7.8m ⬆️mDOR 16.5 vs 9.2m ⬆️ ORR and ⬆️CR 13% vs 8% ↔️Similar G>=3 AEs in both arms ⬇️ dose reductions & tx discontinuation Very exciting results for a new first line option in PD-L1+

5th Plenary #ASCO25: #MATTERHORN Ph III, Durvalumab + FLOT—>✂️—>Durva vs NeoAdj FLOT in resectable GEJ/Gastric Ca. - 2yr EFS 67% vs 59% (HR: 0.71). Improvement regardless of PDL1 - 2yr OS 76% vs 70%. mOS NR - Rate of✂️& number of FLOT similar in both arms - D-FLOT new SoC!

CHALLENGE 👤 Who: Colon cancer survivors post-surgery 🏃 What: Exercise 🕒 How: Brisk walk 30–45 min, 3–4x/week for 3 yrs ⏱️ When: Start within 6 months after chemo 🎯 ⬇️ recurrence 📈 ⬆️ survival 💊 Like a drug, minus the side effects nejm.org/doi/full/10.10… #GIOnc #ASCO25

Most awaited data for #ASCO25 DESTINY-Breast09 1L T-DXd + P 💥 vs THP in HER2+ mBC 🧪 PFS (INV): 40.7 mo vs 20.7 mo HR 0.49 (0.39–0.61) 🎯 PFS (BICR): 40.7 vs 26.9 mo HR 0.56 (0.44–0.71), p<0.00001 📈 24-mo PFS: 70.1% vs 52.1% ✅ CR rate: 15.1% vs 8.5% 🕒 DoR >3 yrs ⚠️ No new

Post #ASCO25 thoughts on the DESTINY-Breast09 trial: T-DXd + pertuzumab extended mPFS to 40.7 months in 1st-line HER2+ metastatic breast cancer (THP: 26.9 months, HR: 0.56). The absolute difference of 13.8 months is a remarkable result! This is a turning point that shifts the

Cilta-cel shows potential for CURE in RRMM❗️ In the CARTITUDE-1 trial, a single infusion of cilta-cel delivered remarkable long-term results in heavily pretreated patients with RRMM. After a median follow-up of 61 months, median overall survival reached 61 months.

Photo of the year for myeloma: Cilta-cel in multi-drug refractory disease From Jagannath, Plasma Cell Pete et al Journal of Clinical Oncology #ASCO25

Pleased to share Phase 2 trial results for low-dose regorafenib in relapsed synovial sarcoma. N=25, 76% previously exposed to pazopanib. 3-month progression-free rate: 56%. Median progression-free survival: 5 mths. ascopubs.org/doi/10.1200/GO… OncoDaily JCO Global Oncology

Recognizing the Top Oncologists from the ASCO 2025 at Times Square. This list is based on the most views on X during #ASCO25. Dr Amol Akhade | Paolo Tarantino | Aakash Desai, MD, MPH, FASCO | Stephen V Liu, MD | Hidehito HORINOUCHI | Toni Choueiri, MD | Yakup Ergün | Neeraj Agarwal, MD, FASCO | Andrea Necchi #LARVOL

🚨 Just out in NEJM: #KEYNOTE689 💉🧠 Periop #pembrolizumab (neoadj + adj) + surgery + RT/CRT improves EFS in resectable LA-#HNSCC. First +ve phase 3 in this space! 🔥 🔹 EFS @ 3 yrs CPS ≥10: 59.8% vs 45.9% CPS ≥1: 58.2% vs 44.9% All pts: 57.6% vs 46.4% 📉 HR ~0.66–0.73 🧪 MPR:

I wrote for #ASCOConnection about the duality of oncology—the quiet heaviness of being both oncologist and dad. The weight doesn’t go away, but you get better at carrying it—and finding meaning in the middle of the mess. What keeps you grounded? ASCO lnkd.in/gxZ5Duuv